AUG 15, 2026 · JOURNAL ARTICLE
Sintilimab plus Bevacizumab biosimilar IBI305 and chemotherapy as a first-line treatment in advanced gastric or gastroesophageal junction adenocarcinoma (SBAGA): a single-arm, phase Ib/II study
Nature Communications
Single-arm Phase II trial with a clear efficacy endpoint (ORR 87.0%) and manageable safety profile, but lacks a randomized comparator and modest sample size, necessitating confirmation in larger RCTs.
Reported
Phase Ib sample size and primary…9; no DLTs observed
Phase II efficacy-evaluable popul…54
Primary endpoint: Objective Respo…87.0%